Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
NOVARTIS NEW ZEALAND LIMITED,Dabrafenib,"Melanoma, stage III/IV with BRAF V600 mutation",Dabrafenib,Recommended for decline,Community and Hospital,Oncology Agents and Immunosuppressants
